Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F P Avis

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Journal of Surgical Oncology|January 1, 1979
Certain aspects of analysis of complement dependent antibody in breast cancer patientsJ P Hindsley, I Avis, J F Newsome, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Journal of Surgical Oncology|January 1, 1979
Certain aspects of analysis of complement dependent antibody in breast cancer patientsJ P Hindsley, I Avis, J F Newsome, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1988
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot studyS L Topalian, D Solomon, F P Avis, et al.
The New England Journal of Medicine|April 9, 1987
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 aloneS A Rosenberg, M T Lotze, L M Muul, et al.
Pageof 2